GlaxoSmithKline (GSK) was downgraded to a Hold Rating at Jefferies
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
BioPharma Dive20h
GSK partners with Flagship startup to hunt for Parkinson’s drugs
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
The Pharma Letter52m
GSK inks multi-target alliance with Versalius
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...
STAT2d
Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more
We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology ...
FierceBiotech1d
GSK inks Parkinson's pact with Flagship's Vesalius for $570M-plus biobucks
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
GSK@100: Reinvention, resilience critical to journey, says MD
GSK celebrates 100 years in India with former MDs, highlighting resilience and reinvention in the pharmaceutical industry.
FiercePharma4d
GSK calls it quits on trade group BIO for 2025, following exits by Takeda, UCB and more
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
GSK Vaccines’ shingles ad campaign warns about the year-round threat
The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.
ENDPOINTS NEWS6d
GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na
Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...
MM&M15h
GSK launches gynecological cancer initiative after survey reveals care gaps
Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...
Business Insider5d
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed yesterday at ...
GlobalData on MSN7d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59
GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...
GSK Steps Up Parkinson’s Focus With US Biotech Deal
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...